Literature DB >> 20067462

More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer.

Seun Ajiboye1, Tristan M Sissung, Nima Sharifi, William D Figg.   

Abstract

The type III transforming growth factor-beta receptor (TGFbetaR3, betaglycan), a tumour suppressor, is the most frequently lost TGFbeta pathway component. This event appears to be very important in the transition of the TGFbeta pathway from having tumour-suppressor activity in early prostate tumour development, to having tumour-promoting activity in metastatic disease. Moreover, loss of the TGFbetaR3 can also affect the cellular response towards testosterone, inhibin/activin, and dysregulate growth-factor pathways that mediate growth and angiogenesis. In this review we discuss how TGFbetaR3 normally functions as an accessory protein in the TGFbeta pathway, how its loss is related to tumour progression, and the treatment implications of TGFbetaR3 loss in individuals with prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20067462      PMCID： PMC6360027          DOI： 10.1111/j.1464-410X.2009.08999.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


  20 in total

Review 1.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

2.  Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling.

Authors:  G C Blobe; W P Schiemann; M C Pepin; M Beauchemin; A Moustakas; H F Lodish; M D O'Connor-McCourt
Journal:  J Biol Chem       Date:  2001-04-25       Impact factor: 5.157

Review 3.  Androgen deprivation therapy for prostate cancer.

Authors:  Nima Sharifi; James L Gulley; William L Dahut
Journal:  JAMA       Date:  2005-07-13       Impact factor: 56.272

Review 4.  Role of transforming growth factor Beta in human cancer.

Authors:  Rebecca L Elliott; Gerard C Blobe
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

Review 5.  Activins and inhibins in endocrine and other tumors.

Authors:  G P Risbridger; J F Schmitt; D M Robertson
Journal:  Endocr Rev       Date:  2001-12       Impact factor: 19.871

6.  Binding of two growth factor families to separate domains of the proteoglycan betaglycan.

Authors:  J L Andres; D DeFalcis; M Noda; J Massagué
Journal:  J Biol Chem       Date:  1992-03-25       Impact factor: 5.157

Review 7.  The contribution of inhibins and activins to malignant prostate disease.

Authors:  G P Risbridger; S L Mellor; S J McPherson; J F Schmitt
Journal:  Mol Cell Endocrinol       Date:  2001-06-30       Impact factor: 4.102

Review 8.  The role of inhibins and activins in prostate cancer pathogenesis.

Authors:  C R Dowling; G P Risbridger
Journal:  Endocr Relat Cancer       Date:  2000-12       Impact factor: 5.678

Review 9.  Regulation of gonadotropins by inhibin and activin.

Authors:  Susan J Gregory; Ursula B Kaiser
Journal:  Semin Reprod Med       Date:  2004-08       Impact factor: 1.303

10.  Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer.

Authors:  Abhik Bandyopadhyay; Long Wang; Fernando López-Casillas; Valentín Mendoza; I-Tien Yeh; LuZhe Sun
Journal:  Prostate       Date:  2005-04-01       Impact factor: 4.104
View more
  8 in total

Review 1.  Proteoglycans in prostate cancer.

Authors:  Iris J Edwards
Journal:  Nat Rev Urol       Date:  2012-02-21       Impact factor: 14.432

2.  [Transforming growth factor β in prostate cancer: cellular effects and basic molecular mechanisms].

Authors:  M B Stope; C Rönnau; T Schubert; D Staar; J Bradl; P Ziegler; A Streitbörger; N Kroeger; U Zimmermann; R Walther; M Burchardt; C Börgermann
Journal:  Urologe A       Date:  2013-03       Impact factor: 0.639

Review 3.  Genome-wide association studies in Africans and African Americans: expanding the framework of the genomics of human traits and disease.

Authors:  Emmanuel Peprah; Huichun Xu; Fasil Tekola-Ayele; Charmaine D Royal
Journal:  Public Health Genomics       Date:  2014-11-26       Impact factor: 2.000

Review 4.  Clinical and Therapeutic Implications of Follistatin in Solid Tumours.

Authors:  Lei Shi; Jeyna Resaul; Sioned Owen; Lin Ye; Wen G Jiang
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

Review 5.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

6.  Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer.

Authors:  Jennifer S Myers; Ariana K von Lersner; Charles J Robbins; Qing-Xiang Amy Sang
Journal:  PLoS One       Date:  2015-12-18       Impact factor: 3.240

7.  MEIS-mediated suppression of human prostate cancer growth and metastasis through HOXB13-dependent regulation of proteoglycans.

Authors:  Calvin VanOpstall; Srikanth Perike; Hannah Brechka; Marc Gillard; Sophia Lamperis; Baizhen Zhu; Ryan Brown; Raj Bhanvadia; Donald J Vander Griend
Journal:  Elife       Date:  2020-06-18       Impact factor: 8.140

8.  TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling.

Authors:  Paloma Bragado; Yeriel Estrada; Falguni Parikh; Sarah Krause; Carla Capobianco; Hernan G Farina; Denis M Schewe; Julio A Aguirre-Ghiso
Journal:  Nat Cell Biol       Date:  2013-10-27       Impact factor: 28.824
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.